You are here

  • Home
  • Archive
  • Volume 11, Issue 6
  • Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma

Article info

Article menu
Immunotherapy biomarkers
Original research
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma

Authors

  • Andrea Gaißler Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyInternal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Jonas Bochem Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyInternal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Janine Spreuer Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyInternal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Shannon Ottmann Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Alexander Martens Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Teresa Amaral Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyCluster of Excellence iFIT (EXC 2180) “Image Guided and Functionally Instructed Tumor Therapies”, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Nikolaus Benjamin Wagner Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyDepartment of Dermatology, Venereology and Allergology, Kantonsspital St Gallen, Sankt Gallen, Switzerland PubMed articlesGoogle scholar articles
  • Manfred Claassen Internal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyDepartment of Computer Science, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Friedegund Meier Skin Cancer Center at the University Cancer Centre and National Center for Tumor Diseases Dresden; Department of Dermatology, Faculty of Medicine and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany PubMed articlesGoogle scholar articles
  • Patrick Terheyden Department of Dermatology, University of Lübeck, Lübeck, Germany PubMed articlesGoogle scholar articles
  • Claus Garbe Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Thomas Eigentler Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Dermatology, Venereology and Allergology, Berlin, Germany PubMed articlesGoogle scholar articles
  • Benjamin Weide Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles
  • Graham Pawelec Department of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tübingen, Tübingen, GermanyHealth Sciences North Research Institute, Sudbury, Ontario, Canada PubMed articlesGoogle scholar articles
  • Kilian Wistuba-Hamprecht Department of Dermatology, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyInternal Medicine I, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, GermanyDepartment of Immunology, Interfaculty Institute for Cell Biology, Eberhard Karls University Tübingen, Tübingen, Germany PubMed articlesGoogle scholar articles

Citation

Gaißler A, Bochem J, Spreuer J, et al
Early decrease of blood myeloid-derived suppressor cells during checkpoint inhibition is a favorable biomarker in metastatic melanoma
Journal for ImmunoTherapy of Cancer 2023;11:e006802. doi: 10.1136/jitc-2023-006802
Online issue publication 
June 07, 2023

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.